BR 3005
Alternative Names: BR-3005; BR3005-1/BR3005-2; BR3005-2/BR3005-1Latest Information Update: 06 Jun 2024
At a glance
- Originator Boryung Pharmaceutical
- Class Antihypercalcaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 03 Apr 2024 Boryung Pharmaceutica completes a phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06289933)
- 28 Mar 2024 Boryung Pharmaceutical completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06289920)
- 04 Mar 2024 Boryung Pharmaceutical initiates a phase I trial in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06289920)